Key terms

About BRKR

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BRKR news

Apr 08 7:01am ET Bruker advances magnet technology for broader adoption of NMR Mar 22 7:40am ET Analysts Offer Insights on Healthcare Companies: Bruker (BRKR), Inspire Medical Systems (INSP) and Pfizer (PFE) Mar 15 9:39am ET China stimulus positive for GE HealthCare, tool companies, says Evercore ISI Mar 01 7:14am ET Bruker price target raised to $102 from $94 at UBS Mar 01 1:10am ET Buy Rating Justified: Strategic Acquisition and Growth Potential Bolster Bruker’s Outlook Feb 28 7:27am ET Bruker to acquire ELITechGroup for EUR 870M in cash Feb 27 8:10am ET Analysts Are Bullish on Top Healthcare Stocks: Bruker (BRKR), Hims & Hers Health (HIMS) Feb 15 1:34am ET Analysts’ Top Healthcare Picks: Savara (SVRA), Bruker (BRKR) Feb 14 10:05am ET Airbnb downgraded, Citi upgraded: Wall Street’s top analyst calls Feb 14 10:05am ET Airbnb downgraded, Citi upgraded: Wall Street’s top analyst calls Feb 14 8:36am ET Bruker price target raised to $81 from $63 at Stifel Feb 14 7:25am ET Bruker price target raised to $84 from $75 at TD Cowen Feb 14 7:18am ET Bruker price target raised to $95 from $80 at Citi Feb 14 7:09am ET Bruker price target raised to $95 from $85 at BofA Feb 13 9:15pm ET Market Perform Rating on Bruker: Balancing Strong Performance with Emerging Risks Feb 13 5:13pm ET Bruker price target raised to $66 from $58 at Goldman Sachs Feb 13 4:26pm ET Bruker upgraded to Overweight at JPMorgan following ‘strong’ guidance Feb 13 4:23pm ET Bruker upgraded to Overweight from Neutral at JPMorgan Feb 13 8:26am ET Bruker’s Strategic Acquisitions Set Stage for Growth: A Buy Rating Feb 12 8:24am ET Bruker Corp Announces Senior Notes Issuance for Corporate Financing Feb 12 8:12am ET Bruker Corp Secures CHF 100M in Senior Notes for Growth and Refinancing Feb 12 8:09am ET Bruker Corp Announces Private Offering and Financial Strategy Feb 07 7:29am ET Bruker announces the acquisition of Japan-based Nanophoton, no terms Feb 06 4:06pm ET Bruker acquires Spectral Instruments Imaging Jan 25 7:18am ET Bruker announces agreement to acquire Chemspeed, no terms Jan 11 1:28am ET Strong Buy on Bruker: Robust Financials and Strategic Acquisitions Fuel Growth Outlook

No recent news articles are available for BRKR

No recent press releases are available for BRKR

BRKR Financials

1-year income & revenue

Key terms

BRKR Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BRKR Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms